ID: ALA178421

Max Phase: Preclinical

Molecular Formula: C31H37N3O6S

Molecular Weight: 579.72

Molecule Type: Small molecule

Representations

Canonical SMILES:  CC(C)CN([C@@H](CCCCNC(=O)OCC1c2ccccc2-c2ccccc21)C(=O)O)S(=O)(=O)c1ccc(N)cc1

Standard InChI:  InChI=1S/C31H37N3O6S/c1-21(2)19-34(41(38,39)23-16-14-22(32)15-17-23)29(30(35)36)13-7-8-18-33-31(37)40-20-28-26-11-5-3-9-24(26)25-10-4-6-12-27(25)28/h3-6,9-12,14-17,21,28-29H,7-8,13,18-20,32H2,1-2H3,(H,33,37)(H,35,36)/t29-/m0/s1

Standard InChI Key:  WPMLSGGBESQETR-LJAQVGFWSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 579.72

Molecular Weight (Monoisotopic): 579.2403

AlogP: 5.08

#Rotatable Bonds: 13

Polar Surface Area: 139.03

Molecular Species: ACID

HBA: 6

HBD: 3

#RO5 Violations: 2

HBA (Lipinski): 9

HBD (Lipinski): 4

#RO5 Violations (Lipinski): 2

CX Acidic pKa: 3.53

CX Basic pKa: 2.29

CX LogP: 4.73

CX LogD: 1.59

Aromatic Rings: 3

Heavy Atoms: 41

QED Weighted: 0.19

Np Likeness Score: -0.59

References

1. Bouzide A, Sauvé G, Yelle J..  (2005)  Lysine derivatives as potent HIV protease inhibitors. Discovery, synthesis and structure-activity relationship studies.,  15  (5): [PMID:15713418] [10.1016/j.bmcl.2004.12.068]

Source

Source(1):

• Scientific Literature